Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Curigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N

Open source

DOI: 10.1016/j.esmoop.2026.106945
Published: 2026 Apr
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.106945,
  title = {Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.},
  author = {Curigliano G and O'Shaughnessy J and Bidard FC and Casalnuovo ML and Kim SB and Tokunaga E and Aftimos P and Saura C and Carey LA and Okera M and Melo E and Zagouri F and Magallanes-Maciel M and Karadurmus N and Bahadur S and Speck RM and Wang XA and Pradhan K and Macey J and Kitchen H and Fairhurst S and Miller J and Jhaveri KL and Harbeck N},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2026.106945},
  url = {https://doi.org/10.1016/j.esmoop.2026.106945}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.
AU  - Curigliano G
AU  - O'Shaughnessy J
AU  - Bidard FC
AU  - Casalnuovo ML
AU  - Kim SB
AU  - Tokunaga E
AU  - Aftimos P
AU  - Saura C
AU  - Carey LA
AU  - Okera M
AU  - Melo E
AU  - Zagouri F
AU  - Magallanes-Maciel M
AU  - Karadurmus N
AU  - Bahadur S
AU  - Speck RM
AU  - Wang XA
AU  - Pradhan K
AU  - Macey J
AU  - Kitchen H
AU  - Fairhurst S
AU  - Miller J
AU  - Jhaveri KL
AU  - Harbeck N
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2026.106945
UR  - https://doi.org/10.1016/j.esmoop.2026.106945
ER  -

APA

G, C., J, O., FC, B., ML, C., SB, K., E, T., P, A., C, S., LA, C., M, O., E, M., F, Z., M, M., N, K., S, B., RM, S., XA, W., K, P., J, M., H, K., S, F., J, M., KL, J., & N, H. (2026). Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.106945

Source records

pubmed · retrieved 2026-09-26T23:12:26.061Z
europe-pmc · retrieved 2026-09-26T23:12:26.077Z